Table of Contents Author Guidelines Submit a Manuscript
Anemia
Volume 2011 (2011), Article ID 435683, 7 pages
http://dx.doi.org/10.1155/2011/435683
Research Article

The Management of Iron Chelation Therapy: Preliminary Data from a National Registry of Thalassaemic Patients

1Consorzio per Valutazioni Biologiche e Farmacologiche, Via L. Porta 14, 27100 Pavia, Italy
2I.RI.D.I.A. srl, Viale Concilio Vaticano II 75/B, 70124 Bari, Italy
3U.S. Dipartimentale Ematologia-DH Talassemia, Ospedale “Madonna delle Grazie”, Via Montescagliaso C. da Cattedra Ambulante 1, 75100 Matera, Italy
4UOC Ematologia-Emoglobinopatie, Ospedale “G. Di Cristina”, Via Benedettini 1, 90100 Palermo, Italy
5Centro Microcitemia, Azienda Ospedaliera “Bianchi Melacrino Morelli”, Via Melacrino 1, 89126 Reggio Calabria, Italy
6U.O. Day Hospital Talassemia, Ospedale “S. Eugenio”, Piazzale Umanesimo 10, 00144 Roma, Italy
7UOS Talassemia Pediatrica ed Emoglobinopatie Pediatriche, Azienda Ospedaliera di Rilievo Nazionale “Antonio Cardarelli”, Via A. Cardarelli 9, 80131 Napoli, Italy

Received 14 January 2011; Revised 28 March 2011; Accepted 11 April 2011

Academic Editor: Yurdanur Kilinç

Copyright © 2011 Adriana Ceci et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. G. Zurlo, P. de Stefano, C. Borgna-Pignatti et al., “Survival and causes of death in thalassaemia major,” The Lancet, vol. 2, no. 8653, pp. 27–30, 1989. View at Google Scholar · View at Scopus
  2. C. Borgna-Pignatti, S. Rugolotto, P. de Stefano et al., “Survival and disease complications in thalassemia major,” Annals of the New York Academy of Sciences, vol. 850, pp. 227–231, 1998. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Borgna-Pignatti, S. Rugolotto, P. de Stefano et al., “Survival and complications in patients with thalassaemia major treated with transfusion and deferoxamine,” Haematologica, vol. 89, no. 10, pp. 1187–1193, 2004. View at Google Scholar · View at Scopus
  4. A. Ceci, P. Baiardi, M. Catapano et al., “Risk factors for death in patients with beta-thalassaemia major: results of a case-control study,” Haematologica, vol. 91, no. 10, pp. 1420–1421, 2006. View at Google Scholar
  5. P. T. Telfer, F. Warburton, S. Christou et al., “Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone,” Haematologica, vol. 94, no. 12, pp. 1777–1778, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. M.-D. Cappellini, A. Cohen, A. Eleftheriou, A. Piga, J. Porter, and A. Taher, Eds., Guidelines for the Clinical Management of Thalassaemia, Thalassaemia International Federation, 2nd edition, 2006.
  7. E. Angelucci, G. Barosi, C. Camaschella et al., “Italian society of hematology practice guidelines for the management of iron overload in thalassemia major and related disorders,” Haematologica, vol. 93, no. 5, pp. 741–752, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. “Consensus view on choice or iron chelation therapy in transfusional iron overload for inherited anaemias,” UK Forum on Haemoglobin Disorders, http://www.haemoglobin.org.uk/pdf/guidelines/Consensus_oral_chelation_v7.pdf.
  9. P. J. Giardina and R. W. Grady, “Chelation therapy in β-thalassemia: an optimistic update,” Seminars in Hematology, vol. 38, no. 4, pp. 360–366, 2001. View at Google Scholar · View at Scopus
  10. S. Beratis, “Noncompliance with iron chelation therapy in patients with β thalassaemia,” Journal of Psychosomatic Research, vol. 33, no. 6, pp. 739–745, 1989. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Politis, “The psychosocial impact of chronic illness,” Annals of the New York Academy of Sciences, vol. 850, pp. 349–354, 1998. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Ward, J. J. Caro, T. C. Green et al., “An international survey of patients with thalassaemia major and their views about sustaining life-long desferrioxamine use,” BMC Clinical Pharmacology, vol. 23, no. 2, article 3, 2002. View at Google Scholar
  13. M. A. Vardaki, A. E. Philalithis, and I. Vlachonikolis, “Factors associated with the attitudes and expectations of patients suffering from β-thalassaemia: a cross-sectional study,” Scandinavian Journal of Caring Sciences, vol. 18, no. 2, pp. 177–187, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Ceci, M. Felisi, V. de Sanctis, and D. de Mattia, “Pharmacotherapy of iron overload in thalassaemic patients,” Expert Opinion on Pharmacotherapy, vol. 4, no. 10, pp. 1763–1774, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. R. K. Basran, F. F. Fassos, D. Shaw, and N. F. Olivieri, “Assessment of the relative quality of life in patients receiving subcutaneous deferoxamine and the orally active iron chelating agent L1,” Blood, vol. 84, no. 10, supplement 1, p. 261a, 1994. View at Google Scholar
  16. L. Zahed, F. H. Mourad, R. Alameddine, S. Aoun, S. Koussa, and A. Taher, “Effect of oral iron chelation therapy with deferiprone (L1) on the psychosocial status of thalassaemia patients,” Haematologia, vol. 31, no. 4, pp. 333–339, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. C. Borgna-Pignatti, M. D. Cappellini, P. de Stefano et al., “Cardiac morbidity and mortality in deferoxamine- or deferiprone treated patients with thalassemia major,” Blood, vol. 107, no. 9, pp. 3733–3737, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Ceci, P. Baiardi, M. Catapano et al., “Risk factors for death in patients with β-thalassemia major: results of a case-control study,” Haematologica, vol. 91, no. 10, pp. 1420–1421, 2006. View at Google Scholar · View at Scopus
  19. R. W. Grady and P. J. Giardinia, “Iron chelation: rationale for combination therapy,” in Iron Chelators: New Development Strategies, D. G. Badman, R. J. Bergeron, and G. M. Brittenham, Eds., The Saratoga Group, Ponte Vedra, Fla, USA, 2000. View at Google Scholar
  20. B. Wonke, C. Wright, and A. V. Hoffbrand, “Combined therapy with deferiprone and desferrioxamine,” British Journal of Haematology, vol. 103, no. 2, pp. 361–364, 1998. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Ceci, P. Baiardi, M. Felisi et al., “The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients,” British Journal of Haematology, vol. 118, no. 1, pp. 330–336, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. European Medicines Agency, “Ferriprox: European Public Assessment Report,” 2010, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000236/WC500022044.pdf.
  23. R. Raghupathy, D. Manwani, and J. A. Little, “Iron overload in sickle cell disease,” Advances in Hematology, vol. 2010, Article ID 272940, 9 pages, 2010. View at Publisher · View at Google Scholar